Lifelong hematopoiesis involves the proliferation and differentiation of successive clones into mature blood lineages. Mono- or oligoclonal hematopoiesis can occur in elderly patients who have somatic TET2 or DNMT3A mutations. The production of blood by one or a few clones with somatic mutations renders patients susceptible to blood disorders such as refractory cytopenias or myelodysplasia. It is unclear which combinations of these mutations are sufficient to promote clonal dominance or maintain malignancy. Here, we have developed a system in the zebrafish to study the genetics of clonality. A Zebrabow fish allows for clonal labeling of stem cells and their progeny with random combinations of three fluorescent proteins, providing enough diversity to produce up to 30 detectable colors. Using a tissue-specific inducible CreERT2 system, we labeled stem cells at 36 hpf of development and then grew the animal to adulthood. This labeled roughly 20 clones of cells, establishing that there are 20 cells of the developing aorta that contributed to adult hematopoiesis. We have also developed tissue-specific CRISPR technology to target multiple genes simultaneously. Using this approach, we will look for gene combinations that are required for clonal hematopoiesis. We then will undertake a chemical screen to find pathways that suppress clonal dominance. Single cell analysis with the Tenen and Orkin labs will be used to examine specific gene expression in particular dominant clones after FACS isolation. We plan to evaluate the activity of the genes and small molecules discovered using the zebrafish in the mouse Hue system (Scadden) and the transposon barcoding strategy (Camargo). Our collaboration with Dr. Orkin will identify chromatin factors required for the establishment of normal clonal dynamics. Our studies will have an impact on understanding early clonal events that regulate normal and malignant hematopoiesis, and could develop novel therapeutics to suppress clonal hematopoiesis.

Public Health Relevance

With aging, normal blood stem cells acquire and accumulate genetic defects that lead to deficiencies in fighting infection, bleeding, and increased potential of transformation to a malignant state. It would be advantageous to find methods to suppress mutant stem cell clones before they lead to a disease state. We plan to use a zebrafish model system to study how the genetically mutated stem cell clones take over the normal blood system and then find chemical compounds that could suppress these clones and restore normal blood production.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Yang, Yu-Chung
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Wattrus, Samuel J; Zon, Leonard I (2018) Stem cell safe harbor: the hematopoietic stem cell niche in zebrafish. Blood Adv 2:3063-3069
Rodriguez-Fraticelli, Alejo E; Wolock, Samuel L; Weinreb, Caleb S et al. (2018) Clonal analysis of lineage fate in native haematopoiesis. Nature 553:212-216
Sridhar, Radhakrishnan; Takei, Hisashi; Syed, Riyaz et al. (2018) Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBP?. Molecules 23:
Gonzalez, David; Luyten, Annouck; Bartholdy, Boris et al. (2017) ZNF143 protein is an important regulator of the myeloid transcription factor C/EBP?. J Biol Chem 292:18924-18936